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I M M U N O L O G Y
Multiplexed enrichment and genomic profiling  
of peripheral blood cells reveal subset-specific  
immune signatures
Miguel Reyes1,2*, Dwayne Vickers1,2*†, Kianna Billman1, Thomas Eisenhaure1, Paul Hoover1,3, 
Edward P. Browne1, Deepak A. Rao3, Nir Hacohen1,4‡, Paul C. Blainey1,2‡
Specialized immune cell subsets are involved in autoimmune disease, cancer immunity, and infectious disease 
through a diverse range of functions mediated by overlapping pathways and signals. However, subset-specific 
responses may not be detectable in analyses of whole blood samples, and no efficient approach for profiling 
cell subsets at high throughput from small samples is available. We present a low-input microfluidic system for 
sorting immune cells into subsets and profiling their gene expression. We validate the system’s technical per-
formance against standard subset isolation and library construction protocols and demonstrate the impor-
tance of subset-specific profiling through in vitro stimulation experiments. We show the ability of this integrated 
platform to identify subset-specific disease signatures by profiling four immune cell subsets in blood from 
patients with systemic lupus erythematosus (SLE) and matched control subjects. The platform has the poten-
tial to make multiplexed subset-specific analysis routine in many research laboratories and clinical settings.
INTRODUCTION
Millions of immune cells can be obtained from a small blood draw, 
yet most methods for immune profiling from clinical samples fail to 
resolve the biological information contained within these cells. Re-
cently, profiling the immune state of individuals using gene expres-
sion analysis of total peripheral blood mononuclear cells (PBMCs) 
has become instrumental in defining immune signatures and disease 
states in humans. These studies provide insight into the mechanisms 
of complex immune responses that occur in infection (1, 2) and auto-
immunity (3–5), which are difficult to recapitulate in murine models 
(6–8). Furthermore, expression signatures can be used to stratify in-
dividuals into different disease subtypes (9–13) or to predict individu-
alized clinical prognoses (14–16). However, profiling total PBMCs has 
a severely limited potential to resolve immune status since PBMCs 
constitute a complex mixture of specific cell types or cell “subsets” 
with distinct functions. Furthermore, no effective methods exist to 
resolve the underlying signatures of immune subsets from a total 
PBMC dataset. Only recently, gene expression profiles from purified 
subset samples have been shown to be better discriminants of immune 
status than total PBMC profiles due to the diversity of leukocyte re-
sponses (17–20). In addition, new immune subsets and cellular states, 
some of which are indicative of impaired immune function, have 
been discovered through gene expression profiling of PBMCs at the 
single-cell level (21–24). These observations have stirred interest in 
probing the gene expression and monitoring the activity of these sub-
sets in particular. As a whole, this developing body of work suggests 
that molecular profiling of PBMC subsets is poised to become an impor-
tant tool in basic studies of immune disease as well as a clinical tool 
useful for predicting and monitoring patient outcomes.
Despite its potential as a tool for immunomonitoring, available 
methods for subset-specific expression profiling are ill-suited for 
large studies and clinical translation. First, technologies for cell sub-
set enrichment such as fluorescence-activated cell sorting (FACS) 
are capital intensive and require substantial attention from highly 
trained staff. As a result, FACS is challenging to scale for large clin-
ical studies with many samples (e.g., multiple cell subsets across 
many patients at different time points). In addition, FACS requires 
a minimum sample input to establish gates for each target subset, 
which can frustrate its application to low-quantity samples and 
projects targeting many subsets from each sample. Another popular 
approach, magnetic affinity cell sorting (MACS), is most often 
practiced manually or on proprietary instrumentation with a capac-
ity to run batches of 6 to 10 enrichments. Although the potential to 
automate MACS at higher throughput using pipetting robots exists, 
this also requires large samples for good results (typically 1 million 
cells per subset), would be capital intensive, requires extensive custom 
programming, and is only effective for central processing centers 
with a large steady supply of samples. Second, the throughput of com-
plex RNA sequencing (RNA-seq) library construction protocols is 
generally limited by reagent cost and labor. Implementing library 
construction at high throughput on custom liquid handling systems 
has been widely demonstrated but suffers the same drawbacks 
described above in reference to a hypothetical automated MACS 
approach. Last, single-cell analysis obviates the need for subset pu-
rification since each cell is profiled individually. However, many 
thousands of cells would need to be analyzed from each sample, 
which is prohibitively expensive today for large studies and particu-
larly inefficient where rare subsets are of interest or immune cells 
make up a small fraction of the total sample (25).
Because of these limitations, most clinical gene expression 
studies are currently limited to whole-blood or total PBMC profiling 
(9–11, 14, 15), which fail to resolve expression signatures from most 
cell subsets due to confounding signals from more abundant cell 
populations. To efficiently identify and monitor important disease 
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signatures in lower-abundance subsets, we developed a multiplexed 
microfluidic system that integrates both human PBMC subset en-
richment and sequence library construction procedures for subset- 
specific genome-wide expression measurements by RNA-seq. Our 
approach has the unique advantage of integrating the subset enrich-
ment and complex multistep RNA-seq library construction proto-
cols to provide an end-to-end solution in a single device that is not 
provided by any other approach. By integrating the key functional-
ity into a single microfluidic device, we eliminate the need to ac-
quire, program, and monitor complex liquid-handling robots or 
integrate a constellation of single-purpose proprietary instruments. 
Here, we show how this integrated workflow can be multiplexed to 
handle multiple cell subsets and sequence libraries in parallel. Because 
no comparable integrated instrumentation exists, we benchmark 
the technical performance of our system against the gold standard 
approaches for each step that are commonly implemented manually 
by expert immunology research laboratories.
The microfluidic system carries out multiplexed enrichment of 
target cell subsets based on affinity for cell surface markers by MACS 
and high-sensitivity sequence library construction for full-length 
RNA-seq using Smart-seq chemistry. From an input of 50,000 cells, 
the device can purify multiple PBMC subsets with high purity and 
produce highly quantitative gene expression data covering about 
10,000 genes in each subset. In testing immune stimulation and 
challenge in vitro, we highlight the importance of subset-specific 
profiling by showing differential responses across four selected sub-
sets. Last, we applied the microfluidic device to profile PBMCs of 
patients with systemic lupus erythematosus (SLE) and identified 
clear differences in the transcriptomic states of healthy individuals 
and patients with SLE in multiple immune cell subsets. By integrat-
ing multiplexed enrichment and library construction workflows in a 
single device, our platform has the potential to enable scalable 
PBMC sample preparation for large clinical studies and allow for 
both high-resolution and high-throughput profiling of the immune 
system. We foresee the routine application of this system as a tool to 
monitor immune responses in clinical studies and help diagnose pa-
tients with complex and/or critical immune conditions.
RESULTS
Microfluidic device design
We designed a custom two-layer microfluidic device capable of 
semiautomated cell isolation, cell disruption, and sequence library 
construction protocols. This system integrates microfluidic liquid 
handling with magnetic affinity purification and capability for on-
board polymerase chain reaction (PCR). The device is fabricated 
using established methods for two-layer soft lithography (26), has 
“large” microliter-scale internal volumes to handle mammalian cell 
samples, and contains 39 micromechanical valve sets controlled by 
an external pneumatic valve controller (27). Each operating unit on 
the device consists of three main chambers, each having different 
capacities (1, 2, and 4 l), that are partitioned by microvalves 
(Fig. 1A). The largest chamber is rectangular in shape and is used 
for cell isolation (Supplementary Note), while the two smaller “rotary 
reactor” chambers are used for library construction (28). These re-
actors are fitted with internal microvalves that are used to formulate 
sample and reagent combinations and to mix these by peristalsis 
around the circular channel (Fig. 1B). Bead resuspension is achieved 
by peristalsis in the rotary reactors and by a moving magnetic field 
in the large rectangular chamber. A 675-m-thick silicon wafer was 
used as the substrate for these microfluidic devices to allow rapid 
heat transfer during temperature changes called for in the protocol, 
particularly for PCR (due to its thinness and high thermal conduc-
tivity). The substrate thinness also enables small external permanent 
magnets to closely approach magnetic beads in the device chambers 
and subject these to strong magnetic forces. The magnets are used 
to move beads between chambers and hold beads in place during 
buffer exchange steps. With such device functionality, we are able to 
automate many steps in the complex protocol for cell sorting, cell 
disruption, and RNA-seq library construction in a simple microar-
chitecture (fig. S1). The three-chamber operating unit is modular 
and constitutes a scalable microarchitecture for devices with vari-
able sample multiplexing capacity. The data presented here were 
produced using 10-channel devices, although we have fabricated 
devices with 6 to 30 channels. The devices can also be reused follow-
ing a simple washing procedure (particular devices were used up to 
four times in this study).
Microfluidic cell sorting and low-input RNA-seq
To validate the performance of our microfluidic device, we inde-
pendently benchmarked the subset enrichment and RNA-seq work-
flows (Fig. 1C) against standard protocols for cell sorting and RNA-seq 
library construction. We tested our workflows using adult PBMC 
samples from healthy subjects obtained from a commercial supplier 
(Research Blood Components) at an input level of 50,000 cells per 
enrichment. We implemented MACS on the microfluidic device and 
configured a high-resolution eight-color flow cytometry analysis to 
read out the purity and yield of the resulting enriched cell subset 
samples (fig. S2). We optimized the conditions for microfluidic 
cell subset isolation by testing different reagents, incubation times, 
and washing procedures and compared the results of the optimized 
microfluidic protocol to conventional benchtop MACS (fig. S3 and 
Methods).
We tested positive selection of target cells, negative depletion of 
nontarget cells (where we recover cells that do not bind to the beads), 
and sequential isolation using both modalities in tandem. The total 
time required for isolation is about 1 hour. The CD4 and CD8 sub-
sets were isolated using the tandem procedure. First, total T cells 
were isolated by depleting cells expressing markers for lineages other 
than T cells. The total T cell population was then positively selected 
for either CD4 or CD8 to isolate helper and cytotoxic T cell subsets 
separately. The previous negative selection reduced contamination 
from nontarget lineages that express CD4 or CD8. B cells and mono-
cytes, on the other hand, were effectively isolated using single positive 
selection for CD19 and CD14, respectively. The device consistently 
achieved good purity (80 ± 8%) and excellent yield (76 ± 21%) for 
multiple targets and modes of isolation (Fig. 2, A and B), leading to 
2- to 13-fold enrichment of the selected cell types. While the device 
workflow does not result in perfect enrichment of the target cell 
type, we found that the purity of the subsets isolated using the opti-
mized microfluidic protocol was similar to those obtained by bench-
top MACS, suggesting that our workflow is on par with current 
implementations used to process clinical immune cell samples (fig. 
S3A). In addition, our device achieved better yield with lower in-
puts than benchtop MACS (fig. S3B). These results show that mi-
crofluidic cell sorting with magnetic beads is a viable alternative to 
conventional sorting approaches and demonstrates the feasibility of 
subset-specific enrichment with limited quantity samples.
 o
n
 February 15, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Reyes et al., Sci. Adv. 2019; 5 : eaau9223     23 January 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
3 of 10
On the basis of the results of our cell isolation testing, we expected 
to capture thousands of cells in each subset using our microfluidic 
device. With these relatively low numbers in mind, we implemented 
a sensitive RNA-seq protocol (Smart-seq2) (29) in the chip with mi-
nor modifications. Instead of solid-phase reversible immobilization 
(SPRI)–based cleanup for RNA extraction, we used custom-prepared 
poly-dT capture beads (Methods) that captured mRNA molecules 
in lysate by direct hybridization to enable purification and subse-
quent solid-phase reverse transcription. Our protocol calls for am-
plifying the resulting complementary DNA (cDNA) molecules by 
PCR, purifying the products with SPRI, and subsequently recover-
ing the samples from the device for transposase- based fragmentation 
and adaptation with subsequent enrichment PCR closely following 
the standard Smart-seq2 method. The timing for this procedure 
closely follows the Smart-seq2 protocol (about 2 hours hands-on 
time plus 5 hours for incubations). The cDNA amplicons from the 
microfluidic device showed the expected size distribution, and the 
RNA-seq datasets resulting from these samples show high techni-
cal reproducibility (Pearson correlation of 0.88 ± 0.04) and cor-
relate well with libraries produced using the standard Smart-seq2 
protocol on the benchtop across four different cell subsets (0.90 ± 
0.03) (Fig. 2D, fig. S4, and Table 1). Despite the overall similarity 
between the gene expression profiles of the four subsets (Fig. 2C), 
the sequence libraries produced in our workflow can distinguish 
the subsets based on simple correlation and clustering procedures 
(Fig. 2E). In addition, the enrichment of polyadenylated RNA in the 
microfluidic protocol reduced the number of ribosomal RNA reads 
and improved transcript mapping rates over the standard Smart-seq2 
protocol (Table 1 and fig. S5). Combining RNA-seq with cell isola-
tion in an integrated workflow yields libraries of similar quality as 
standard processing approaches (Table 1 and figs. S6 and S7). These 
results demonstrate that full-length cDNA synthesis and amplifica-
tion by PCR can be implemented in a microfluidic device with in-
put from on-device–enriched cell subsets to support RNA-seq 
and that reduction in the reaction volume and reagent consump-
tion (from 25 to 2 l) does not negatively affect the quality of li-
braries obtained.
Gene expression signatures of PBMCs stimulated in vitro
We assessed how accurately and reproducibly our system can pro-
file the dynamic immune responses of different cell subsets and to 
what extent the responses were stereotypic or subset specific. We 
cultured healthy PBMCs and applied three distinct treatments known 
to affect immune cells [lipopolysaccharide (LPS), interferon- (IFN-), 
and dexamethasone (DEX)] in duplicate. Using the microfluidic 
device to carry out multiplexed subset enrichments and RNA-seq 
library construction, we profiled the treatment response of three 
different subsets (CD4+ T cells, B cells, and CD14+ monocytes). The 
Fig. 1. Microfluidic chip design and integrated workflows. (A) Photograph of a 10-channel chip filled with yellow, blue, and red dye to highlight compartments; control 
valves are filled with green dye. Scale bar, 2 cm. The inset shows the diagram of one channel, where compartments and control lines are colored similar to the photograph. 
Red and black arrows indicate sample input/output and reagent input ports, respectively. Blue arrows indicate control valves that control flow through the channels. 
(B) Schematic showing key device capabilities that enable various sample preparation steps. Black arrows indicate mixing valves that alternately open and close to gen-
erate flow within a compartment, allowing for reagent mixing and bead resuspension without external fluid input. Permanent magnets are used for moving magnetic 
beads across different compartments or preventing their flow during buffer exchange and washes. (C) Full and partial (cell sorting and RNA-seq) sample preparation 
workflows implemented in the microfluidic chip.
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device-processed libraries again showed strong reproducibility, co-
clustering the duplicates based on differential gene expression re-
sponses (Fig. 3A and fig. S8) and accurately recording differences in 
responses to the three treatments (Fig. 3B and fig. S9).
Furthermore, our results highlight the heterogeneity in response 
between different cell subsets (Fig. 3, C and D), as evidenced by the 
minimal overlap in differentially expressed genes and enriched path-
ways among the three subsets profiled. Even in the canonical Jak-
STAT (signal transducer and activator of transcription) signaling 
pathway, which is known to be directly activated by IFN-, the pat-
tern of downstream responses varied substantially across the three 
subtypes studied here (Fig. 3E). These results are consistent with 
previous reports that type I IFNs can have either proliferative or 
suppressive effects on lymphocytes, depending on the relative tim-
ing of receptor coactivation (30). In addition, these responses are 
greatly affected by cell-to-cell communication and the interplay be-
tween innate and adaptive immunity (31–33). After 24 hours of stimu-
lation, IFN- induces a strong proliferative response in B cells as 
shown by the up-regulation of cell cycle and metabolism pathways, 
while for monocytes, this effect is not observed (Fig. 3D). This finding 
is in line with previous studies (34–40) showing that IFN- directly 
stimulates B cells to induce a strong antiviral response and a commit-
ment to an effector phenotype, while in monocytes, the effect of IFN- 
is costimulatory and primes monocytes to differentiate into dendritic 
cells after further stimulation. Together, these results emphasize the 
importance of subset-specific profiling to resolve differences that 
would be obscured in total PBMC expression profiling.
Transcriptomic profiling of SLE patients
To demonstrate the utility of the device for disease studies, we pro-
filed the immune state of five patients with SLE and five healthy 
control individuals by isolating CD4+ T cells, CD8+ T cells, B cells, and 
CD14+ monocytes (plus a negative control) in duplicate from cryo-
preserved PBMC samples (for a total of 100 subset isolations and 
RNA-seq libraries including controls; table S1). For each sample, 
0.5 million cells were split into eight channels on devices to isolate 
four subsets in duplicate and prepare RNA-seq libraries (Supplementary 
Methods). While we detected only a few differentially expressed 
genes when performing single-gene analyses (fig. S10), we found that 
gene sets with targets of IFN are up-regulated in patients with SLE 
Fig. 2. Chip performance and validation. (A and B) Representative purity (black bars), yield (gray bars), and composition of immune cell types after microfluidic sorting. 
Yield is determined relative to fraction of the target subset in the input sample. (C) Pearson correlations between RNA-seq libraries of the four cell subsets processed 
through the microfluidic chip. (D) Scatterplot showing technical replicability of standard and microfluidic RNA-seq. Red points indicate genes with greater than twofold 
change between replicates. (E) Correlation matrix between standard and microfluidic RNA-seq libraries for four FACS-sorted cell lysates with single positive markers (CD4, 
CD8, CD14, and CD19). Error bars indicate SD (n = 3).
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compared to matched healthy control subjects based on gene set enrich-
ment analyses (41), in line with our expectation that gene set enrich-
ment analysis would have higher statistical power than analysis of 
single gene expression (Fig. 4A). This finding is in agreement with 
other studies that show the role of type I IFNs in the pathogenesis of 
SLE (42, 43) and validates the robustness of our method in identify-
ing disease-relevant signatures. We found that IFN targets are en-
riched across all four subsets, which is expected based on previous 
profiling studies of cells from SLE patients (20, 44–46). Gene targets 
of the fusion protein NUP98-HOXA9, a potent driver of myeloid 
leukemia, were also enriched in all subsets. This supports previous-
ly published evidence that dysregulated lymphocyte proliferation 
is associated with both cancer and autoimmune disease and could 
explain the increased risk of malignancy in patients with SLE (47).
Last, to further compare our results with previous studies, we 
generated an IFN gene score based on a panel of SLE signature genes 
established from previous studies that were not cell subset–resolved 
(Supplementary Methods and fig. S11) (48). Our data show that while 
this signature can be found across all the subsets we profiled, the 
difference between healthy and SLE signature scores is much more 
pronounced in B cells (P = 0.05 for B cells, P ≥ 0.2 for other subsets; 
with Bonferroni correction for testing multiple subsets) (Fig. 4B). 
This suggests that the diagnostic sensitivity and predictive power of 
the IFN signature for SLE may be improved by specifically profiling B 
cells instead of total PBMCs. Together, these initial findings show that 
gene expression responses in SLE differ across immune cell subsets 
and highlight the importance of subset-specific profiling in identify-
ing disease signatures.
DISCUSSION
Through our multiplexed microfluidic workflow, we demonstrate 
the utility of subset-specific profiling of immune cells and its advan-
tages over conventional total PBMC or total blood transcriptomics. 
Subset-specific analysis allows ready detection of biological signals 
from minority subsets by reducing confounding effects from abun-
dant cell populations such as the monocytes that dominated our test 
samples. Our method is complementary to the application of single- 
cell transcriptomics approaches. For example, single-cell studies 
could reveal pathogenic subsets that can be enriched using the 
microfluidic device for large-scale research studies or clinical 
diagnostics, even for rare subsets. With this framework, single-cell 
RNA-seq (scRNA-seq) can be initially applied to a small cohort at a 
single time point to identify clinically relevant subsets, after which, 
the integrated subset-specific microfluidic workflow can be used to 
scale up to a larger cohort with multiple time points, increasing the 
study’s resolution and statistical power while lowering its cost. An-
other example would be the application of cell subset enrichment to 
target cells of interest ahead of scRNA-seq. This type of workflow 
could markedly improve the efficiency of scRNA-seq studies that 
target rare cell subsets by reducing the number of nontarget cells that 
need to be processed and sequenced to gain access to information 
about rare cells of interest.
Here, we describe the design and operation of a single microfluidic 
device that integrates both cell subset isolation and transcriptomic 
profiling, benchmark its performance, and demonstrate its applica-
bility to clinical samples. The device can reliably isolate cell subsets 
of interest and reproducibly construct RNA-seq libraries for next- 
generation sequencing. The sample multiplexing capability and free 
scaling of our microfluidic MACS implementation to low numbers 
of input cells while maintaining good enrichment performance are 
key advantages over conventional MACS approaches. Furthermore, 
the microfluidic device can be readily repurposed for other library 
preparation techniques, such as chromatin accessibility and DNA 
methylation profiling. We highlighted the importance of subset- 
specific profiling through in vitro treatment of healthy PBMCs and 
the clinical utility of the workflow by profiling cell subsets in multi-
plex from patient samples with SLE. While our protocols do not yet 
reach the purity levels of FACS, the on-device enrichment approach 
boosts the signal from target subsets relative to total PBMC profiles 
by a significant 2- to 13-fold, enabling robust detection of weaker 
signals. This platform will enable high-resolution monitoring of 
immune responses in clinical studies, especially in applications where 
blood samples or other inputs bear limited numbers of target cells 
and large-scale immunomonitoring studies where significant sam-
ple throughput is required.
METHODS
Study samples
Human blood samples were obtained either from Research Blood 
Components (MA, USA) for technical validation experiments or 
from collections at the Brigham and Women’s Hospital (MA USA) 
(table S1). Research on the samples was approved by Institutional 
Table 1. RNA-seq library statistics for the samples generated in this study. Two technical replicates are performed for each sample and isolated subset;  
n represents the total number of RNA-seq libraries generated for each column. Values are shown as means ± SD. rRNA, ribosomal RNA. 
Benchtop Microfluidic
Lysates (n = 12) Lysates (n = 12) PBMCs (n = 10) Cultured PBMCs  (n = 24)
SLE PBMCs 
(clinical study)  
(n = 32)
Healthy PBMCs 
(clinical study)  
(n = 34)
Estimated library size 
(millions) 16.1 ± 1.7 12.4 ± 5.5 7.7 ± 5.47 13.0 ± 8.7 6.3 ± 4.6 8.9 ± 3.6
Genome map rate (%) 91.6 ± 8.7 88.9 ± 1.7 86.8 ± 2.5 77.0 ± 16.3 79.8 ± 6.3 82.5 ± 5.7
Transcript map rate (%) 48.0 ± 7.0 63.0 ± 10.0 45.0 ± 15.0 65.0 ± 13.0 61.9 ± 10.5 63.1 ± 8.7
Gene count 13,592 ± 512 10,850 ± 481 10,336 ± 848 8899 ± 1379 9091 ± 1956 9817 ± 1757
rRNA (%) 8.67 ± 1.76 0.22 ± 0.06 2.48 ± 1.17 0.56 ± 0.37 1.29 ± 1.07 1.34 ± 1.08
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Fig. 3. Genomic characterization of PBMCs treated in vitro. (A) Unsupervised clustering of untreated (NT) and treated (DEX, IFN, and LPS) PBMC subsets based on differen-
tially expressed genes (false discovery rate < 0.05). Venn diagrams showing numbers of (B) treatment-specific differentially expressed genes for each subset and (C) subset- 
specific differentially expressed genes for each treatment. (D) Gene set enrichment analysis (Reactome sets, FDR < 0.01) of IFN-treated B cells and monocytes. Red nodes indicate 
up-regulation, while blue nodes indicate down-regulation. Node sizes are proportional to the number of genes in the gene set, while edge lengths are inversely proportional to 
the number of overlapping genes between the sets. (E) Normalized fold change (FC) in expression of Jak-STAT pathway genes in IFN-treated samples over untreated controls. 
Each node shows the fold-change expression of each gene in the three subsets profiled (left block, monocytes; middle block, B cells; right block, CD4 T cells).
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Review Boards at the Broad Institute of Massachusets Institute of 
Technology (MIT) and Harvard (MA, USA) and Brigham and 
Women’s Hospital (MA, USA). Blood samples from patients with 
SLE and healthy control donors were drawn with EDTA Vacutainer 
tubes (BD Biosciences) and processed within 3 hours of collection.
Isolation of PBMCs from whole blood
Cells were isolated from whole blood samples using density gradi-
ent centrifugation. Whole blood was diluted 1:1 with 1× phosphate- 
buffered saline, layered on top of Ficoll-Paque PLUS (GE Healthcare), 
and centrifuged at 1200g for 20 min. The PBMC layer was retrieved, 
resuspended in 10 ml of RPMI-1640 (Gibco), and centrifuged again 
at 300g for 10 min. The cells were counted using a manual hemocy-
tometer, resuspended in fetal bovine serum (FBS) (Gibco) with 10% 
dimethyl sulfoxide (Sigma), and aliquoted in 1-ml cryopreservation 
tubes at a concentration of 5 million cells/ml. The tubes were kept at 
−80°C overnight and then transferred to liquid nitrogen for long-term 
storage. Before processing, cells were thawed at 37°C for 3 min, re-
suspended in 10 ml of RPMI-1640 supplemented with 10% FBS 
(Gibco), and centrifuged at 300g for 5 min. The cells were then re-
suspended in the desired concentration or buffer, depending on the 
experiment.
Microfluidic device design and fabrication
The microfluidic device was fabricated using a previously published 
protocol (27) with minor modifications. Flow layer molds were pat-
terned in three steps: (i) rectangular (75 m), (ii) rectangular (200 m), 
and (iii) rounded (60 m). All silicon wafers were precoated with 
hexamethyldisilazane (Sigma) before spin coating. Rectangular fea-
tures were prepared by spin-coating SU-8 2075 (MicroChem) on a 
silicon wafer. The coated wafers were patterned by ultraviolet (UV) 
exposure (OAI 206 mask aligner) through a mask printed at 20,000 dots 
per inch (Fineline Imaging, design files are included in the Supple-
mentary Materials). The features were then developed using an SU-8 
Fig. 4. Transcriptional immune profiling of SLE patients. (A) Enriched gene sets (MSigDB C2) in SLE samples compared to healthy controls. P values are adjusted for 
multiple gene set testing (Benjamini-Hochberg). (B) Heat map showing relative IFN-signature scores across different cell types of 10 patients. Scores (transcripts-per- 
million sum for 37 genes; Supplementary Methods) are mean-centered across each subset. The dendrogram shows clustering of patients based on IFN-signature scores 
for B cells. The asterisk indicates missing data due to technical dropout.
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developer (MicroChem). The rounded features were produced by spin- 
coating an AZ-40XT photoresist (MicroChem), patterning the wafer 
with UV exposure and a mask, and developing with an AZ 400K de-
veloper (MicroChem). After development, the wafer was subjected 
to an additional curing step (105°C for 10 min) to round the fea-
tures. The control layer mold was patterned in one step: rectangular 
(40 m), using methods similar for the flow layer with an SU-8 2015 
photoresist (MicroChem). Device production was carried out using 
standard soft lithography, following the same published protocol, 
with the exception of final bonding to a silicon wafer substrate.
Magnetic affinity cell isolation and  
microfluidic implementation
Magnetic affinity cell sorting was done using commercially avail-
able EasySep kits (CD14, CD19, CD4, and CD8 positive isolation II 
and T cell negative isolation) from STEMCELL Technologies. To 
implement the isolation protocols on the device, the buffers were 
modified and volumes were scaled accordingly. EasySep buffer 
(STEMCELL Technologies) was supplemented with 10% FBS (Gibco) 
and 0.2% Pluronic-F127 (Sigma), to reduce nonspecific cell adhe-
sion in the polydimethylsiloxane channels. The microchannels were 
also preincubated with 1% Pluronic-F127 (Sigma) before cell isola-
tion. Neodynium magnets (Grainger) with a 43-lb pull were used 
for all magnetic capture steps.
Flow cytometry and FACS
For assessment of isolation purities, flow cytometry was conducted 
using the Cytoflex system (Beckman Coulter). For RNA-seq library 
validation experiments and benchtop comparisons, PBMCs were 
sorted using the MoFlo Astrios (Beckman Coulter). Lysate pools 
were generated by sorting 5000 cells into 20 l of TCL buffer (Qiagen) 
and  1 l proteinase K (20 mg/ml; Qiagen) and stored at −80°C to main-
tain RNA integrity. The following panel was used for both purity 
assessment and sorting: DAPI, CD45 BV605, CD3 AF700, CD4 FITC, 
CD8 PE, CD14 APC, CD19 PE-Cy7, and CD56 BV650 (all IgG1, 
BioLegend). Flow cytometry data were analyzed using FlowJo v10.1.
Low-input RNA-seq, microfluidic implementation,  
and sequencing
RNA-seq was performed using Smart-Seq2 (29) with minor modifi-
cations. Cells were sorted into 19 l of TCL buffer and 1 l proteinase 
K (20 mg/ml; Qiagen), and their RNA was purified by a 2.2× SPRI 
cleanup with RNAClean XP magnetic beads (Agencourt) before re-
verse transcription. For the microfluidic implementation of the 
protocol, Tween 20 (Teknova) was added to all reactions at a final 
concentration of 0.5%. For mRNA capture, a biotinylated oligo 
(/5BiosG/ - AAGCAGTGGTATCAACGCAGAGTAC-30T-VN) 
(Integrated DNA Technologies) was attached to streptavidin mag-
netic beads (New England Biolabs) following the manufacturer’s 
protocol. The beads were then used to capture mRNA from the ly-
sates and were washed with 10 mM tris-HCl (pH 7.5), 0.15 M LiCl, 
1 mM EDTA, and 0.5% Tween 20. The beads were then resuspended 
in the reverse transcription mix, following the same steps as the 
published protocol. cDNA processed on the benchtop and micro-
fluidic device were amplified for 18 and 22 cycles, respectively. After 
amplification and cleanup, libraries were quantified using a Qubit 
fluorometer (Invitrogen), and their size distributions were deter-
mined using the Agilent Bioanalyzer 2100. After normalizing the 
amplicon concentrations to 0.1 to 0.2 ng/ml, sequencing libraries were 
constructed using the Nextera XT DNA Library Prep Kit (Illumina), 
following the manufacturer’s protocol. All RNA-seq libraries were 
sequenced with 38 × 37 paired-end reads using a MiniSeq or NextSeq 
(Illumina).
In vitro stimulation of PBMCs
Healthy PBMCs were resuspended in RPMI-1640 supplemented with 
10% FBS and 1× penicillin-streptomycin (Gibco). Cells were cultured 
at a density of 1 M/ml and stimulated with LPS (5 g/ml) (eBioscience), 
DEX (100 nM) (Millipore), IFN- (250 U/ml) (Abcam), or no treat-
ment. The cells were cultured for 24 hours at 37°C in a 5% CO2 en-
vironment before processing through the microfluidic device.
RNA-seq data analysis
RNA-seq libraries were sequenced to a depth of 5 to 15 million 
reads per sample. All technical validation libraries were subsampled 
to 10 million reads to remove potential confounding effects of se-
quencing depth. Sequencing reads were aligned to the UCSC hg19 
transcriptome using STAR (49) and used as input to generate QC 
statistics with RNA-SeQC (50). RSEM (51) was used to generate an 
expression matrix for all samples. Both raw count and transcripts 
per million data were analyzed using edgeR and custom R scripts. 
Lowly expressed genes with log2 (counts per million) less than 5 were 
filtered out before analysis. Gene set analyses were performed using 
the Kolmogorov-Smirnov test implementation in GAGE (52). Cyto-
scape and the enrichMap (53) module extension were used to visu-
alize pathway-specific differential expression data.
SUPPLEMENTARY MATERIALS
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